000520.KS KSC
Samil Pharmaceutical Co.,Ltd
1W: +6.2%
1M: +38.7%
3M: +27.4%
YTD: -21.2%
1Y: -13.6%
3Y: +16.4%
5Y: +0.1%
₩8,600.00 ($6.41)
+400.00 (+4.88%)
Weekly Expected Move ±8.2%
₩7186
₩7893
₩8600
₩9307
₩10014
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$371.6B
-5.9% ▼
5Y CAGR: +14.2%
Total Liabilities
$238.3B
+8.9% ▲
5Y CAGR: +13.2%
Shareholders Equity
$133.3B
-24.3% ▼
5Y CAGR: +16.0%
Cash & Investments
$6.4B
+24.8% ▲
5Y CAGR: -17.9%
Total Debt
$164.0B
+9.3% ▲
5Y CAGR: +11.7%
Net Debt
$157.6B
+8.7% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $4.0B | $1.9B | $906M | $5.1B | $6.4B |
| Short-Term Investments | $11.3B | $0 | $0 | $0 | $819K |
| Cash & ST Investments | $15.3B | $1.9B | $906M | $5.1B | $6.4B |
| Net Receivables | $31.1B | $34.2B | $35.8B | $35.8B | $37.3B |
| Inventory | $24.2B | $24.7B | $32.5B | $34.8B | $34.8B |
| Other Current Assets | $6.1B | $14.0B | $11.9B | $3.1B | $0 |
| Total Current Assets | $76.7B | $74.8B | $81.1B | $91.3B | $82.0B |
| Property, Plant & Equip. | $103.4B | $233.9B | $242.2B | $252.9B | $242.7B |
| Goodwill & Intangibles | $1.3B | $3.1B | $2.8B | $5.5B | $5.5B |
| Long-Term Investments | -$10.4B | $782M | $797M | $720M | $37.5B |
| Other Non-Current Assets | $1.2B | $83.4B | $44.5B | $44.6B | $3.9B |
| Total Non-Current Assets | $149.7B | $281.9B | $289.6B | $303.7B | $289.6B |
| Total Assets | $226.4B | $356.7B | $370.7B | $395.1B | $371.6B |
| — Liabilities — | |||||
| Accounts Payable | $8.5B | $13.7B | $21.0B | $19.2B | $19.2B |
| Short-Term Debt | $92.3B | $85.5B | $124.7B | $63.3B | $141.2B |
| Deferred Revenue | $17.5B | $868M | $0 | $0 | $97M |
| Other Current Liabilities | -$8.1B | $28.1B | $19.3B | $8.7B | $24.3B |
| Total Current Liabilities | $121.7B | $132.6B | $168.7B | $106.7B | $185.2B |
| Long-Term Debt | $31.9B | $71.9B | $49.6B | $84.4B | $21.6B |
| Other Non-Current Liab. | $5.8B | $11.7B | $13.6B | $18.7B | $23.8B |
| Total Non-Current Liabilities | $39.0B | $98.3B | $74.2B | $112.3B | $53.2B |
| Total Liabilities | $160.7B | $230.9B | $242.9B | $218.9B | $238.3B |
| — Equity — | |||||
| Common Stock | $6.8B | $6.9B | $7.6B | $10.8B | $10.8B |
| Retained Earnings | $27.7B | $26.6B | $1.9B | $19.9B | -$38.4B |
| Accumulated OCI | $1.4B | $56.0B | $52.3B | $61.7B | $76.9B |
| Total Stockholders Equity | $65.7B | $125.8B | $127.8B | $176.1B | $133.3B |
| Total Liabilities & Equity | $226.4B | $356.7B | $370.7B | $395.1B | $371.6B |
| — Key Metrics — | |||||
| Total Debt | $125.5B | $159.3B | $175.9B | $150.1B | $164.0B |
| Net Debt | $121.5B | $157.4B | $175.0B | $144.9B | $157.6B |
| Total Investments | $839M | $782M | $797M | $720M | $37.5B |